Filing Flows › ClearPoint Neuro (CLPT) › Q3 2026
ClearPoint Neuro (CLPT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
ClearPoint Neuro (CLPT) reported revenue of $12.1M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +11% from the quarter before. Operating margin was -52.4%, net loss $7.5M (61.8% of revenue).
ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%, net loss $7.5M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.1M | +11% | +36% |
| Operating profit | −$6.3M | — | — |
| Net earnings | −$7.5M | — | — |
| Operating cash flow | −$5.1M | — | — |
What changed
Revenue was $12.1M in Q3 2026, up 36% year over year and up 11% from the previous quarter. Service was the largest line at 35% of revenue. Capital Equipment and Software added $705K year over year (up 68%), 22% of the total change. Biologics and Drug Delivery Disposable Products declined 8%.
Gross margin was 58.5%, down 4.7 points from Q3 2025. Operating costs exceeded revenue by $6.3M, an operating margin of -52.4%. Operating expenses grew 23% against revenue growth of 36%. The fastest-growing cost line was Other operating costs (+44%). The quarter ended with a net loss of $7.5M, narrower than the previous quarter's $11.3M loss.
Operating cash flow was −$5.1M. Non-cash charges added back $103K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $365K. Capital expenditures of $137K exceeded it, leaving free cash flow of −$5.2M.
Questions
What was ClearPoint Neuro's revenue in the third quarter 2026?
ClearPoint Neuro (CLPT) reported revenue of $12.1M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +11% from the quarter before.
Was ClearPoint Neuro profitable in the third quarter 2026?
Operating loss was $6.3M (-52.4% of revenue) and net loss $7.5M.
Source: ClearPoint Neuro 10-Q on SEC EDGAR.